MindWalk News and Activities
Presence
MindWalk develops biotechnology and AI tools for brain and health research. Its products include data analysis software and research services for biotech companies, healthcare groups, and academic labs.
MindWalk products and services overview:
- AI research tools
- Data analysis software
- Biomarker discovery
- Clinical data tools
Revenue: ~$1 million
Employees: 15
Headquarters: Toronto, Canada
MindWalk is one of the...
MindWalk is a company listed under the stock ticker IPA (CA).
Acquisition, funding and merger involving MindWalk.
- MindWalk is now listed under ticker HYFT. (posted on September 3 2025).
- The new name of ImmunoPrecise is MindWalk. (posted on September 3 2025).
Executives
View the org chart displaying its 20 main executives
Most searched biographies at MindWalk
- Jennifer Bath, Chief Executive Officer and President
- Kamil Isaev, Director
- Dirk Witters, Chairman of the Board
Create your alert
to follow the executive moves at MindWalk.
Biotechnology
MindWalk has 2,425 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).
Popular M&A news in Biotechnology
- Chemomab and Scipher Medicine have announced they will merge (posted on July 13 2026)..
- Apnimed has filed its IPO. Its stock ticker will be APMD. (posted on July 13 2026).
- The new name of EG 427 is Cyllene Therapeutics. (posted on July 10 2026).
Popular contacts in Biotechnology
News
Press releases by MindWalk
- MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery
- MindWalk Holdings Corp. (NASDAQ: HYFT) Launches ReefIQ™, a Biological Context Layer for AI Drug Discovery
- MindWalk's Preclinical Dengue Data Support a HYFT® Computational Prediction: Immunogens Designed on the Predicted Target Elicited Cross-Reactive Antibodies Against Antigens of All Four Dengue Serotypes, Reproduced Across Two Independent Campaigns
- MindWalk Holdings Deploys Pandemic Response Platform via HYFT® Technology as Ebola and Hantavirus Outbreaks Expose the Limits of Strain-Specific Coverage
- The Biology Came First.
- MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results
- MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results
- MindWalk Announces B Cell Llama™, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era
- MindWalk Holdings Corp. to Report Third Quarter Fiscal Year 2026 Financial Results on March 12, 2026
- MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics
- View more press releases Close
Social media about MindWalk
- MindWalk on Wikipedia, Google News & Yahoo Finance
- MindWalk on LinkedIn, X (Twitter) & YouTube
